Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07590193 · ClinicalTrials.gov registry record · Phase 1
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT07590193 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 162 participants.
The verdict
NCT07590193, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG AMG 127
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2027-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07590193
The ClinicalTrials.gov registry entry for NCT07590193 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07590193 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07590193 about?
NCT07590193 is a clinical study titled "A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus". The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT07590193?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2026-06-11. Estimated completion is 2027-10-02.
What interventions are being tested in trial NCT07590193?
The interventions under investigation include: Placebo (DRUG), AMG 127 (DRUG).
Who is sponsoring clinical trial NCT07590193?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.